MarketInOut Stock Screener Log In | Sign Up

Genmab A/S ADR

NASDAQ • Healthcare • Biotechnology • Quote as of 10/30/2026
Genmab A/S ADR stock price and volume chart

Company Profile

IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization35,520 mln
Float587 mln
Earnings Date11/05/2026

EPS

1.27
Stretched

P / E

44.93
High premium

Piotroski F-Score

4 / 9
Borderline

Beneish M-Score

-3.85
Highly reliable

1-Year Forecast

48.27
Downside risk

Relative Strength

99 / 100
Top performer

Business Description

Founded in Denmark in 1998, Genmab is a biotechnology company focused on developing antibody-based treatments for cancer and other serious diseases. Its commercial portfolio includes therapies for blood cancers such as multiple myeloma and lymphoma, cervical cancer, thyroid eye disease, multiple sclerosis, and other conditions, with several more treatments in various stages of development targeting solid tumors, blood disorders, and additional cancer types. The company works alongside a broad network of partners, including Johnson & Johnson, Pfizer, AbbVie, Amgen, and BioNTech, among others.

Key Fundamentals

EPS1.27
P/E44.93
ROE13.77
RPS6.71
ROIC15.81
ROA7.65
Interest Cover4.96
EBITDA, mln1,267
EV / EBITDA24.22
EV / EBIT26.16
Revenue, mln4,127
EV / Revenue7.43

Quote Details

Last 57.06
Change 0.57 (1.01%)
Open 57.40
Volume 8,625,805
Turnover 492,188,448
Average Volume 6,517,027

Financial Ratios

Pre-Tax Profit Margin22
Leverage Ratio2.10
Current Ratio2.46
Price / Book4.54
Price / Cash Flow39.62
Price / Free Cash Flow33.35
Debt / Equity0.89
Price / Sales7.12
PEG Ratio2.15

Financial Strength

Altman Z-Score3.49
Piotroski F-Score 4 / 9
Beneish M-Score-3.85
Price to Intrinsic Value1.70
Price to Lynch Fair Value1.22
1-Year Target Price48.27
Shiller PE Ratio43.79
Short Ratio1.67
Short % of Float1.09

Price Performance & Relative Strength

Period Price Performance Relative Strength
1 Week 30.3% 99 / 100   
1 Month 65.15% 99 / 100   
2 Months 98.13% 99 / 100   
6 Months 116% 99 / 100   
1 Year 97.1% 97 / 100   



Disclaimer - Privacy Policy - Terms of Service - Cookies - FAQ - Affiliates - Blog